Thanks, Dew....would appreciate a follow up to the CC at 11:00 am which I will be unable to listen to since I have to go for rehab on my pinched nerve...(I saw your Tweet this am)....
Based on today’s CC, the company's guidance for annualized cash burn has been lowered to $45M.
ADXS’ current cash balance is $59.2M less whatever was burned during the fiscal quarter ended 10/31/18 (#msg-143423885, bottom). Assuming ~$14M of cash burn during the fiscal quarter ended 10/31/18 (#msg-143474369), ADXS’ cash balance at 10/31/18 is about $45M.
Thus, ADXS now has about 12 months of operating cash.
ASXS: Yes the neoantigen vaccine had me going till I read this link posted here last year, which suggested that ADXS's approach must also possibly wait for other outcome interventions to re-adjust (customize) the bio-environment for a patient to be most receptive to this neo-antigen approach. https://investorshub.advfn.com/boards/read_msg.aspx?message_id=143963471&txt2find=adxs